KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $3.0 billion.

  • Vertex Pharmaceuticals' Accumulated Expenses rose 654.81% to $3.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.0 billion, marking a year-over-year increase of 654.81%. This contributed to the annual value of $3.0 billion for FY2025, which is 654.81% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Accumulated Expenses of $3.0 billion as of Q4 2025, which was up 654.81% from $3.6 billion recorded in Q3 2025.
  • Vertex Pharmaceuticals' Accumulated Expenses' 5-year high stood at $3.6 billion during Q3 2025, with a 5-year trough of $1.5 billion in Q2 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $2.6 billion (2023), whereas its average is $2.5 billion.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 696.76% in 2021, then soared by 4296.26% in 2022.
  • Vertex Pharmaceuticals' Accumulated Expenses (Quarter) stood at $1.7 billion in 2021, then increased by 26.69% to $2.1 billion in 2022, then rose by 24.86% to $2.7 billion in 2023, then grew by 5.02% to $2.8 billion in 2024, then rose by 6.55% to $3.0 billion in 2025.
  • Its Accumulated Expenses was $3.0 billion in Q4 2025, compared to $3.6 billion in Q3 2025 and $3.3 billion in Q2 2025.